1. PrEP: A Case-by-Case Approach

2. Program Goals

3. Case 1: Serodiscordant Male Couple

4. Options to Consider

5. Promoting Condom Use

6. HPTN 052: Study Design

7. HPTN 052: HIV Transmission Events

8. HPTN 052: HIV Transmission Events (cont)

9. HIV Preexposure Prophylaxis

10. Risk Reduction by Drug Concentration in iPrEx

11. CDC Interim Guidance on PrEP Use

12. PrEP, Antiretroviral Therapy, or Both for Serodiscordant Couples?

13. Antiretroviral Therapy vs PrEP vs Both: Key Decision Points

14. Case 2: A Popular Young Man

15. Efficacy of Oral Tenofovir/Emtricitabine PrEP in Patient Subgroups

16. iPrEx: Predictors of Adherence

17. PrEP Use and Social Harms

18. HIV Infections During PrEP Trials in the United States

19. Case 3: Flu-like Illness

21. Acute HIV Infection

22. Case 4: PrEP in Women?

23. Efficacy of Daily Oral Emtricitabine/Tenofovir PrEP in Women

24. Adherence is the Key Factor for PrEP Efficacy

25. PrEP Can Facilitate Antiretroviral Therapy for the Infected Partner

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)

29. References

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)